First-in-human evaluation of an astrocytic glutamate transporter (EAAT2) pet tracer in healthy and alzheimer's diseased brain
Active Project Grant Awarded Last action
- Award ID
- R01AG072743
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,643,675
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 87% complete
- Originally
- Place of performance
- San Francisco, CA 94107, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) and related dementias represent a growing public health concern with tremendous impact on patients and their families. Efforts to treat ad effectively are partially confounded by different hypotheses regarding its initiation and progression. The varying hypotheses are reflected in the range of highly informative imaging methods used to study ad and its progression, such as positron emission tomography (pet) targeted to specific cerebral proteins. In this project we will develop a novel [18F]-labeled pet imaging tracer, RP-115, to evaluate changes in astrocytes in healthy versus cognitively impaired ad patients by quantitative pet imaging of the excitatory amino acid transporter 2 (EAAT2) that is primarily localized on astrocytes and is significantly down-regulated in select cerebral regions of ad brain. The project hypothesis is that regional cerebral decreases of RP-115 tracer binding to astrocyte EAAT2 detected by pet imaging in live human brain can be used as an early and sensitive measure of ad onset and progression. The first-in-human project objective is composed with two translational development goals: 1) to establish RP-115 tracer human safety, and 2) to utilize the tracer to assess regional cerebral EAAT2 tracer binding differences in healthy VS. AB-, ptau- and cognitively-defined ad patients; and compare the EAAT2 ad data to existing ad FDG and MAO-b astrocytic-related pet profiles. We will test the hypothesis and satisfy the translational project objective by accomplishing three specific aims. Aim 1: establish RP-115 safety in the clinic with male and female pet imaging. Aim 2: acquire RP-115 EAAT2 imaging data in well-defined male and female healthy control and ad patient cohorts. Aim 3: analyze the pet imaging data.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $804,521 | |
| Amendment | $804,521 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $824,846 | |
| Amendment | $824,846 | |
| Amendment | $816,825 | |
| Amendment | $784,058 | |
| Original award | $784,058 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| RIO Pharmaceuticals LLC | $880,448 |
Quick answers
Who received award R01AG072743?
R01AG072743 was awarded to The Regents Of The University Of California. San Francisco by National Institute on Aging (National Institutes of Health) on August 15, 2022.
How much is award R01AG072743 worth?
$5,643,675 has been obligated on R01AG072743.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award